What urolithin A is — and why longevity clinics are asking
Urolithin A is not a vitamin or a plant compound you eat directly. It is a metabolite: your gut bacteria produce it after you eat ellagitannins and ellagic acid, the polyphenols concentrated in pomegranate, walnuts and some berries. Interest has grown quickly among healthy-ageing and performance clinics because urolithin A is one of the most-studied natural inducers of mitophagy — the housekeeping process by which cells recycle damaged mitochondria. As mitophagy slows with age, mitochondrial quality falls, and this is thought to contribute to the loss of muscle strength and energy that patients describe.
For a clinic in KL or Singapore already discussing CoQ10, NAD+ precursors or resveratrol with patients, urolithin A sits naturally in the same conversation. What sets it apart is a delivery problem that food cannot solve.
How urolithin A works in the body (pharmacology)
Urolithin A’s primary described mechanism is the induction of mitophagy — the selective autophagic clearance of damaged mitochondria. Worn-out mitochondria leak reactive oxygen species and produce less ATP; ageing cells accumulate them because the recycling machinery slows. Urolithin A has been reported to promote the recognition and lysosomal disposal of these defective organelles, which in turn supports mitochondrial biogenesis — the replacement of the discarded pool with new, better-functioning mitochondria. The downstream consequences observed in models are improved mitochondrial respiratory capacity in muscle, reduced oxidative stress, and a dampened inflammatory signal, consistent with the lower C-reactive protein and acylcarnitine levels reported in human trials. Because it is the finished metabolite, it acts without requiring the bacterial conversion step that dietary precursors depend on. These are mechanistic findings that explain how the molecule behaves in the body; they are not a promise of a clinical outcome in any individual patient.
The “producer problem”: why diet alone rarely works
Here is the fact that makes urolithin A a compounding topic rather than a grocery one. The conversion of dietary precursors into urolithin A depends on specific gut bacteria — Gordonibacter and certain Enterocloster species — and a large share of people simply do not carry enough of them.
The numbers are striking. In one study of 100 healthy adults, only about 12% had detectable urolithin A at baseline. After drinking pomegranate juice, only around 40% converted the precursors into meaningful amounts. Across populations, somewhere between roughly 10% and 60% are classed as “non-producers,” with the proportion shifting by diet and geography — one analysis placed about 14% of a Chinese cohort in the non-producer group. Producers tend to have greater gut-microbiome diversity; non-producers cannot fix the gap simply by eating more pomegranate.
The practical implication for prescribers: you cannot assume a patient benefits from ellagitannin-rich foods, and you usually cannot tell who converts without specialised testing. Direct supplementation with urolithin A side-steps the lottery — research shows that giving the finished metabolite achieves consistent blood levels across a population regardless of microbiome type.
What the human trials actually show
The evidence base is still young, so language matters — these are early findings, not settled outcomes. In a four-month randomised, placebo-controlled trial in middle-aged adults, urolithin A was associated with roughly a 12% improvement in muscle strength, along with better aerobic endurance and physical performance, and lower plasma markers of inflammation (C-reactive protein) and mitochondrial stress (acylcarnitines) (Singh et al., Cell Reports Medicine, 2022). A 2025 randomised trial published in Nature Aging examined 1,000 mg daily over 28 days for effects on age-related immune decline. Larger studies — including the biggest urolithin A trial to date, looking at brain health in around 650 participants — are expected to report in 2026.
| Muscle strength | ≈ +12% |
| Aerobic endurance (peak VO₂ / 6-min walk) | Improved |
| Inflammation marker (CRP) | Reduced |
| Mitochondrial stress (acylcarnitines) | Reduced |
Source: Singh et al., Cell Reports Medicine, 2022. Independent published study — not Lynnity data, and not a promise of individual results.
Studies suggest urolithin A is promising for mitochondrial and muscle health in ageing adults, but it is not a treatment for any disease, and results should be framed to patients as supportive rather than curative.
The bioavailability challenge — why the formulation decides the outcome
Urolithin A is highly lipophilic and poorly soluble in water, which limits how much survives digestion and reaches the bloodstream from an ordinary powder or capsule. This is where delivery science earns its place. Encapsulating urolithin A in a liposomal (phospholipid) or lipid-matrix system has been shown to improve its oral bioavailability substantially — one liposomal preparation raised relative bioavailability roughly three-fold versus the free compound in preclinical work.
Liposomal delivery is one of Lynnity’s two core strengths, so for a lipophilic active like urolithin A, an absorption-optimised liquid or capsule is a rational default rather than an afterthought. A commercial tablet or fixed-dose softgel, by contrast, gives the prescriber no control over either the dose or the delivery base. If you would like the underlying science, our explainer on the science of liposomal delivery covers how these vesicles are built.
Where compounding adds value
- Precise dose. Trials have used 250 mg to 1,000 mg; a prescriber can select, say, 500 mg or 1,000 mg to match the patient and the goal, rather than accepting a manufacturer’s single strength.
- Delivery form that fits the molecule. A liposomal oral liquid or an absorption-optimised capsule addresses urolithin A’s poor solubility; a sublingual or flavoured liquid can help patients who struggle with capsules.
- Rational combinations. For mitochondrial support, urolithin A can be combined with actives a clinic already uses — for example CoQ10 or ubiquinol — into a single daily capsule, reducing pill burden.
- Excipient control. For sensitive or allergy-prone patients, the formula can be prepared free of specific fillers, dyes or allergens.
Lynnity compounds in capsule, liquid, cream, tonic and serum forms only; for urolithin A the relevant choices are a capsule or a liposomal oral liquid.
Safety, dose and cautions
Urolithin A has a reassuring early safety profile. It received US FDA GRAS (Generally Recognised As Safe) status in 2018 for doses of 250–1,000 mg, and human trials at 500–1,000 mg daily for up to four months have reported good tolerability, with mild gastrointestinal symptoms the most common complaint and no serious adverse events. Liver, kidney and cardiac markers stayed within normal ranges in these studies.
Two honest caveats belong in every patient conversation: safety data currently extends only to a few months, so daily use over years is not yet characterised; and urolithin A has not been studied in pregnancy, breastfeeding or children, so it should not be prescribed in those groups outside specialist supervision. As with all Lynnity products — including supplements — urolithin A is prescription-only and is dispensed against a registered doctor’s prescription.
Working with Lynnity from KL, the Klang Valley or Singapore
The workflow is designed for practitioners. A doctor assesses the patient and issues a patient-specific prescription; Lynnity’s pharmacists then prepare the formulation to that prescription under Good Compounding Practice (GCP) and dispense it. Clinics in the Klang Valley and Singapore can discuss dose, delivery form and combinations with the pharmacy team before prescribing. Lynnity does not sell direct to the public and does not offer contract manufacturing — every preparation is a personalised, doctor-prescribed formulation.
Frequently asked questions
Can patients just eat pomegranate or take a pomegranate extract instead?
Not reliably. Because only about 40% of people convert the precursors efficiently, and non-producers cannot correct this through diet, food-based approaches give unpredictable results. Direct urolithin A produces consistent levels regardless of microbiome type.
Is urolithin A the same as resveratrol or NAD+ precursors?
No, though they are often discussed together in longevity practice. Resveratrol is a plant polyphenol and NAD+ precursors (NMN, NR) feed a different pathway; urolithin A works mainly by promoting mitophagy. Some clinics use them alongside one another.
What dose does Lynnity compound?
Whatever the prescription specifies, typically within the studied 250–1,000 mg range. Common choices are 500 mg or 1,000 mg once daily.
Does it need a prescription in Malaysia?
Yes. All Lynnity formulations, including supplements, are prepared only against a registered doctor’s prescription.
Which delivery form is best?
Because urolithin A is fat-soluble and poorly water-soluble, a liposomal oral liquid or an absorption-optimised capsule is usually preferred over a plain powder.
Can it be combined with other supplements?
Yes. Compatible actives such as CoQ10 or ubiquinol can be combined into one capsule to simplify a patient’s routine, subject to the prescriber’s plan.
Reviewed by the Lynnity Clinical Compounding Team — registered pharmacists compounding to Good Compounding Practice (GCP) in Kuala Lumpur.
This article is for healthcare professionals and general education. It does not diagnose, treat or cure any disease, and it is not a substitute for individual medical advice. Urolithin A formulations are prescription-only and are prepared under Good Compounding Practice (GCP).